We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.39 | 1.30% | 30.48 | 30.40 | 30.50 | 30.52 | 30.31 | 30.32 | 1,121,708 | 21:15:26 |
By Colin Kellaher
Merck & Co. on Wednesday said it has launched Ontruzant, a biosimilar of Roche Holding AG's blockbuster breast-cancer drug Herceptin, in the U.S.
The Kenilworth, N.J., drug maker said it is rolling out Ontruzant in the U.S. at a list price of about $1,325 for a 150-milligram single-dose vial and $3,709 for a 420-milligram multiple-dose vial, representing a 15% discount to the current list price of Herceptin.
Biosimilars are near-copies of biologic drugs, such as Herceptin, that are made from living cells and are analogous to generic copies of traditional pill-form medicines.
Merck is launching Ontruzant in the U.S. as part of a 2013 development and commercialization agreement with Samsung Bioepis, a joint venture of Samsung BioLogics Co. and Biogen Inc., which received Food and Drug Administration approval for the biosimilar in January 2019.
Samsung Bioepis said the launch makes Ontruzant its first oncology biosimilar available in the U.S.
Merck, which in February announced plans to spin off products from its women's health, legacy brands and biosimilars businesses into an independent, publicly traded company, said it will continue to support the commercialization of Ontruzant until the spinoff, which is slated for the first half of 2021.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 15, 2020 08:22 ET (12:22 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions